Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial).

MLA

Reaume, M.Neil, et al. “Economic Analysis of a Randomized Phase III Trial of Gemcitabine plus Vinorelbine Compared with Cisplatin plus Vinorelbine or Cisplatin plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer (Italian GEMVIN3/NCIC CTG BR14 Trial).” Lung Cancer (Amsterdam, Netherlands), vol. 82, no. 1, Oct. 2013, pp. 115–20. EBSCOhost, https://doi.org/10.1016/j.lungcan.2013.07.012.

APA

Reaume, M. N., Leighl, N. B., Mittmann, N., Coyle, D., Hirsh, V., Seymour, L., Tu, D., Shepherd, F. A., Graham, B., Gridelli, C., Perrone, F., Di Maio, M., Bradbury, P. A., & Evans, W. K. (2013). Economic analysis of a randomized phase III trial of gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer (Italian GEMVIN3/NCIC CTG BR14 trial). Lung Cancer (Amsterdam, Netherlands), 82(1), 115–120. https://doi.org/10.1016/j.lungcan.2013.07.012

Chicago

Reaume, M Neil, Natasha B Leighl, Nicole Mittmann, Doug Coyle, Vera Hirsh, Lesley Seymour, Dongsheng Tu, et al. 2013. “Economic Analysis of a Randomized Phase III Trial of Gemcitabine plus Vinorelbine Compared with Cisplatin plus Vinorelbine or Cisplatin plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer (Italian GEMVIN3/NCIC CTG BR14 Trial).” Lung Cancer (Amsterdam, Netherlands) 82 (1): 115–20. doi:10.1016/j.lungcan.2013.07.012.